OrthoPediatrics (KIDS) Stock Forecast & Price Target

OrthoPediatrics is benefiting from a clear new-product super-cycle and share gains in a pediatric orthopedics market that management described as favorable, with 3Q revenue rising 19% year over year to $72.7 million and beating expectations by about 6%. Trauma & Deformity and Scoliosis both posted strong growth, while higher-ASP launches like 3P Hip and VerteGlide, plus OPSB clinic expansion, are creating a longer runway for revenue, margin expansion, and contracting leverage. Although adjusted EBITDA of $6.9 million missed on timing-related headwinds, the company raised FY26 revenue guidance to $270 million-$273 million, kept adjusted EBITDA guidance at $25 million, and expects positive free cash flow from 2027 onwards.

OrthoPediatrics is facing a constrained growth outlook because its penetration into a specialized pediatric orthopedic TAM appears to be increasing, leaving limited room to accelerate meaningfully above current levels. The company’s ability to convert product launches into revenue remains uncertain, while less share gain than expected and margin expansion below expectations could prevent operating leverage from materializing. Competitive pressure from larger healthcare firms and smaller differentiated entrants, plus concentration risk, acquisition/integration risk, and liquidity risk, further weaken the fundamental case and support a negative stance.